Vildagliptin: A review of its use in the management of type 2 diabetes mellitus

Drugs

Volumn 68, Issue 16, 2008, Pages 2387-2409

  Croxtall, Jamie D ^a,b   Keam, Susan J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Evaluations; Type 2 diabetes mellitus; Vildagliptin, general

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADRENERGIC RECEPTOR STIMULATING AGENT; AMLODIPINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CIMETIDINE; CORTICOSTEROID; DIGOXIN; EUCREAS; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; METFORMIN PLUS VILDAGLIPTIN; MIGLITOL; PIOGLITAZONE; PLACEBO; RAMIPRIL; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; THIAZIDE DIURETIC AGENT; THYROID HORMONE; UNCLASSIFIED DRUG; VALSARTAN; VILDAGLIPTIN; VOGLIBOSE; WARFARIN;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FLATULENCE; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; INSULIN SENSITIVITY; INSULIN TREATMENT; KIDNEY FAILURE; LACTIC ACIDOSIS; LIMB PAIN; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOARTHRITIS; PANCREAS ISLET CELL FUNCTION; PERIPHERAL EDEMA; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 55049090992     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/0003495-200868160-00009     Document Type: Review

References (89)

1. International Diabetes Federation. Diabetes atlas: executive summary third edition [online]. Available from URL: http://www.eatlas.idf.org [Accessed 2008 Jun 17]
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2005: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31
3. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58
4. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2006 Jan; 29 Suppl. 1: S4-42
5. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: the task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association of the Study of Diabetes (EASD) [online]. Available from URL: http://www.escardio.org/guidelines-surveys/esc-guidelines/Guidelines-Documents/ guidelines-diabetes-FT.pdf [Accessed 2008 Oct 10]
6. Clemens A, Siegel E, Gallwitz B. Global risk management in diabetes: blood glucose, blood pressure, and lipids. Update on the background of current guidelines. Exp Clin Endocrinol Diabetes 2004; 112: 493-503
7. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 Nov 11; 368 (9548): 1696-705
8. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 36 (11-12): 867-76
9. Deacon CF, Holst JJ. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int J Biochem Cell Biol 2006; 38 (5-6): 831-44
10. Cvetkovic RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 2007; 67 (6): 935-54
11. Henness S, Keam SJ. Vildagliptin. Drugs 2006; 66 (15): 1989-2001
12. Novartis Pharmaceuticals UK Ltd. Galvus 50 mg tablets [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2008 Jun 17]
13. Novartis Parmaceuticals UK Ltd. Eucreas 50 mg/850 mg film-coated tablets [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2008 Jun 17]
14. Del Prato S. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes. Int J Clin Pract Suppl 2007 Aug; (154): 38-48
15. Pratley RE, Schweizer A, Rosenstock J, et al. Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2007 Dec 17; 10 (10): 931-8
16. Ahren B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl 2008 Mar; 62 (Suppl. 159): 8-14
17. Wajchenberg BL. β-Cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007 Apr; 28 (2): 187-218
18. He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007 May; 47 (5): 633-41
19. Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008 Jan; 31 (1): 30-5
20. Azuma K, Radikova Z, Mancino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008 Feb; 93 (2): 459-64
21. Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007 May; 56 (5): 1475-80
22. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007 Apr; 92 (4): 1249-55
23. El-Ouaghlidi A, Rehring E, Holst JJ, et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 2007 Nov; 92 (11): 4165-71
24. Utzschneider KM, Tong J, Montgomery B, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves β-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008 Jan; 31 (1): 108-13
25. Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed β-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008 Jan; 93 (1): 103-9
26. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007 Apr; 30 (4): 890-5
27. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007 Mar; 9 (2): 166-74
28. He YL, Horowitz A, Watson CE, et al. Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes. J Clin Pharmacol 2007 Jan; 47 (1): 127-31
29. Ahren B, Pacini G, Foley JE, et al. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005 Aug; 28 (8): 1936-40
30. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005 Aug; 90 (8): 4888-94
31. Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006 Jun; 38 (6): 423-8
32. Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005 Nov; 7 (6): 692-8
33. Meece J. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Curr Med Res Opin 2007; 23 (4): 933-44
34. Dejager S, Razac S, Foley JE, et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007 Mar; 39 (3): 218-23
35. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007 Apr; 76 (1): 132-8
36. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007 Feb; 30 (2): 217-23
37. Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 2007 Sep; 24 (9): 955-61
38. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007 Jun; 50 (6): 1148-55
39. Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008; 10 (1): 82-90
40. Ahren B, Pacini G, Tura A, et al. Improved meal-related insulin processing contributes to the enhancement of β-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res 2007 Nov; 39 (11): 826-9
41. Lankas GG, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005 Oct; 54 (10): 2988-54
42. Vella A, Bock G, Giesler PD, et al. The effect of dipeptidyl peptidase 4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double blind, placebo-controlled crossover study. Clin Endocrinol (Oxf). Epub 2008 Mar 10
43. Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008 Feb 1; 10 (8): 675-82
44. Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. Epub 2008 Feb 18
45. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008 Mar 13; 25 (4): 435-41
46. Fonseca V, Baron M, Shao Q, et al. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. Epub 2008 Mar 11
47. Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. Epub 2008 Mar 18
48. European Medicines Agency. Galvus scientific discussion [online]. Available from URL: http://www.emea.europa.eu [Accessed 2008 Jun 17]
49. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85 (1): 9-24
50. Dunning BE, Ligueros-Saylan M, D'Alessio DA, et al. Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naive and metformin-treated patients with type 2 diabetes [abstract no. 0174]. Diabetologia 2006 Sep 3; 49 Suppl. 1: 110-1
51. Iwamoto Y, Kashiwagi A, Yamada N, et al. Vildagliptin versus voglibose monotherapy in patients with type 2 diabetes mellitus: superior efficacy and tolerability with vildagliptin [abstract no. 561-P]. 68th Annual Scientific Sessions of the American Diabetes Association; 2008 Jun 6-10; San Francisco (CA)
52. Ahren B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004 Dec; 27 (12): 2874-80
53. Nathwani A, Lebaut A, Byiers C, et al. Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes [abstract no. 474-P]. Diabetes 2006; 55 Suppl. 1: A113
54. He YL, Sadler BM, Sabo R, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007; 46 (9): 787-802
55. Sunkara G, Sabo R, Wang Y, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol 2007 Sep; 47 (9): 1152-8
56. He YL, Sabo R, Campestrini J, et al. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol 2007; 65 (3): 338-46
57. He YL, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007; 46 (7): 577-88
58. Serra DB, He YL, Wang Y, et al. Combination of the DPP-4 inhibitor vildagliptin (LAF237) with pioglitazone is safe and well tolerated with no pharmacokinetic interaction [abstract no. 2192-PO]. Diabetes 2005 Jun 1; 54 Suppl. 1: A528
59. He YL, Sabo R, Picard F, et al. Lack of pharmacokinetic interaction between vildagliptin and metformin in patients with type 2 diabetes [abstract no. PIII-16]. Clin Pharmacol Ther 2006 Feb; 79 (2): 62
60. Barilla D, He Y, Balez S, et al. No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide [abstract no. 1967-PO]. Diabetes 2004 Jun 4; 53 Suppl. 2: A470
61. He YL, Sabo R, Riviere GJ, et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007 May; 23 (5): 1131-8
62. He YL, Sabo R, Sunkara G, et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007 Aug; 47 (8): 998-1004
63. Thuren T, Byiers S, Mohideen P, et al. Vildagliptin is safe and well tolerated in patients with mild or moderate renal impairment [abstract no. 74]. 44th Annual Meeting of the European Association for the Study of Diabetes; 2008 Sep 7-11; Rome
64. He YL, Flannery B, Campestrini J, et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin 2008 May 7; 26 (6): 1703-9
65. Kikuchi M, Abe N, Kato M, et al. Vildagliptin decreases HbA(1c) after 12 week treatment in Japanese patients with type 2 diabetes. Diabetologia 2006 Sep; 49 Suppl. 1: 478
66. Goke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Met Res. Epub 2008 Aug 22
67. Rosenstock J, Pi-Sunyer FX, Pratley RE, et al. Robust efficacy of vildagliptin in drug-naive patients: pooled analysis of 5 monotherapy studies [abstract no. 506-P]. 67th Annual Scientific Sessions of the American Diabetes Association; 2007 Jun 22-26; Chicago (IL), A135
68. Garber AJ, Sharma MD. Update: vildagliptin for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2008 Jan; 17 (1): 105-13
69. Kothny W, Gimpelewicz C, Byiers S, et al. Cardiovascular safety profile of vildagliptin, new DPP-4 inhibitor for the treatment of type 2 diabetes [abstract no. 915]. 44th Annual Meeting of the European Association for the Study of Diabetes; 2008 Sep 7-11; Rome
70. Data on file. Novartis Pharmaceuticals. Summary of clinical safety. 2007 Dec 5
71. Novartis AG. Galvus® receives European approval as new treatment for type 2 diabetes with broad range of indications [media release]. 2007
72. American College of Endocrinology. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocrin Pract 2002 Jan; 8: 1-82
73. Royal College of General Practitioners. Clinical guidelines for type 2 diabetes. [online]. Available from URL: http://www.nice.org.uk/guidance/index. jsp?action=by-Id&o=10911&history=t [Accessed 2008 Oct 10]
74. National Institute for Clinical Excellence. Type 2 diabetes (update): national clinical guideline for the management in primary and secondary care [online]. Available from URL: http://www.nice.org.uk [Accessed 2008 May 27]
75. Nathan D, Buse J, Davidson M, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29 (8): 1963-72
76. Nathan D, Buse J, Davidson M, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008; 31 (1): 173-5
77. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358 (24): 2545-59
78. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358 (24): 2560-72
79. Lyseng-Williamson KA. Sitagliptin. Drugs 2007; 67 (4): 587-97
80. Deeks ED, Keam SJ. Rosiglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2007; 67 (18): 2747-79
81. Deeks ED, Scott LJ. Pioglitazone/metformin. Drugs 2006; 66 (14): 1863-77
82. Ahren B. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag 2008; 4 (2): 383-94
83. Wellington K. Rosiglitazone/metformin. Drugs 2005; 65 (11): 1581-92
84. Merck and Co. I. Januvia™ (sitagliptin) tablets: full prescribing information. 2006 Oct
85. National Institute for Health and Clinical Excellence. Type 2 diabetes newer agents [online]. Available from URL: http://www.nice.org.uk/guidance/ index.jsp?action=byID&o=11866 [Accessed 2008 Oct 16]
86. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 2007 Apr; 23 (4): 919-31
87. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007 Jul 11; 298 (2): 194-206
88. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008 Apr 16; (2): CD006739
89. Novartis. Efficacy of fixed combination therapy of vildagliptin and metformin components in drug naive patients with type 2 diabetes [ClinicalTrials.gov identifier NCT00382096]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2008 Aug 1]